BioLineRx (NASDAQ:BLRX) Rating Reiterated by HC Wainwright

BioLineRx (NASDAQ:BLRX)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $21.00 price objective on the biotechnology company’s stock.

Separately, StockNews.com upgraded shares of BioLineRx to a “sell” rating in a report on Friday, April 12th.

BioLineRx Trading Down 2.9 %

Shares of NASDAQ BLRX traded down $0.02 during midday trading on Wednesday, reaching $0.62. 330,698 shares of the stock were exchanged, compared to its average volume of 398,791. BioLineRx has a 52-week low of $0.61 and a 52-week high of $2.53. The stock has a 50 day moving average price of $1.09 and a 200-day moving average price of $1.35. The company has a market capitalization of $49.61 million, a P/E ratio of -0.69 and a beta of 1.38. The company has a current ratio of 1.53, a quick ratio of 1.47 and a debt-to-equity ratio of 0.50.

BioLineRx (NASDAQ:BLRX) last released its earnings results on Thursday, March 28th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. The company had revenue of $4.80 million during the quarter, compared to analysts’ expectations of $0.17 million. During the same quarter in the previous year, the firm posted ($0.09) earnings per share. Equities research analysts expect that BioLineRx will post -1.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioLineRx

Several institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC grew its stake in BioLineRx by 278.0% during the fourth quarter. Renaissance Technologies LLC now owns 257,900 shares of the biotechnology company’s stock worth $152,000 after buying an additional 189,678 shares during the period. LPL Financial LLC lifted its position in shares of BioLineRx by 6.4% during the second quarter. LPL Financial LLC now owns 125,210 shares of the biotechnology company’s stock worth $200,000 after purchasing an additional 7,500 shares in the last quarter. Atria Wealth Solutions Inc. acquired a new position in shares of BioLineRx during the first quarter worth $178,000. Envestnet Asset Management Inc. acquired a new position in shares of BioLineRx during the first quarter worth $88,000. Finally, PVG Asset Management Corp acquired a new position in shares of BioLineRx during the fourth quarter worth $97,000. 1.56% of the stock is currently owned by hedge funds and other institutional investors.

BioLineRx Company Profile

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.